Caribou Biosciences price target raised to $34 from $26 at Brookline

Brookline raised the firm’s price target on Caribou Biosciences (CRBU) to $34 from $26 and keeps a Buy rating on the shares. Caribou plans to initiate a CB-010 phase III trial in the second half of 2025, should data confirm improved outcomes for patients receiving a partially human leukocyte antigen matched dose of CB-010 and following an agreement with the FDA on a pivotal trial design, the analyst tells investors in a research note. Caribou plans to report ANTLER initial data from both the 2L large B cell lymphoma and CD19 relapsed cohorts in the first half of the year upon confirmation of improved outcomes in additional patients receiving a partially HLA matched dose of CB-010, and plans to initiate a pivotal phase III trial in 2L LBCL patients, including patients regardless of HLA type, in the second half, the firm adds.